Atea Pharmaceuticals, Inc.

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals fourth quarter 2025 financial results and business update conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open up the call for your questions. I would now like to turn the call over to Janae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed. Thank you.

Great, thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals' fourth quarter and full year 2025 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateapharma.com. With me today from Atea are our Chief Executive Officer and Founder, Dr. John-Pierre Sommadosi, Chief Development Officer, Dr. Janet Hammond, Chief Commercial Officer, John Vavrica, Chief Medical Officer, Dr. Aranjahorga, and Chief Financial Officer and Executive Vice President of Legal, Andrea Porkrin, who will be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainty. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Janae. Good afternoon, everyone, and thank you for joining us. I will begin on slide three. I am pleased to report that we have made substantial clinical progress in the last year advancing our global Phase III program, evaluating the regimen of Benifazovir and Rizazvir for the treatment of HCV infections. Due to the rigorous execution of our two pivotal Phase III trials, C-Forward and CBR, we expect top-line readouts this year for both trials. We also presented federal data sets reinforcing the potential best-in-class profile of our regiment at the ESO Congress in 2025 and the LIVER meeting 2025, the annual meeting of ASLD. Janet will discuss highlights from these presentations. We convened two panel discussions with key opinion leaders that underscore the need for a new optimized HCV regimen to address treatment paradigm shifts, including the test and treat model of care, and how our regimen is uniquely positioned to address the current needs of patients and prescribers and expand the market in the U.S. In November, we announced the expansion of our antiviral hepatitis pipeline to address a major unmet medical need for immunocompromised patients living with chronic hepatitis E infection, a liver disease for which there is currently no approved therapy available. If left untreated, it can rapidly progress to cirrhosis within three to five years. In vitro and in vivo result presented last month at CORE 2026 and at the J.P. Morgan Healthcare Conference in January, support our lead product candidate, AT587, as a potential first-in-class inhibitor against HEV infection. I will review this exciting program later in the presentation. Moving to slide four, I'm pleased to report that our global Phase III HCV program is on track. In December, we completed enrollment for our North American trial, CBR, with over 880 patients, and we expect to complete enrollment C4 outside of North America by mid-year. We anticipate top-line results for CBR mid-year and for C4 by year-end. Following our selection of 8587, As the lead product candidate in our HEV program, we initiated IND and CTA enabling studies and anticipate initiating a first in human study mid-year. Importantly, with $301.8 million of cash, cash equivalent and marketable securities as of December 31st, 2025, We are in the strong financial position to execute and complete our Phase III HCV program and advance our new HEV development program. We anticipate our cash runway will extend through 2027. With that, I will now turn the call over to Janet to review the profile of our regimen.